Alpha Casts - AI Market Intelligence
A late-stage AstraZeneca trial miss and Apollo’s caution about a slower AI payoff punctuate a day of mixed corporate beats and governance moves. Investors are parsing strong consumer prints in apparel and petrol windfalls against legal and pipeline risks, while debates intensify over whether to lean risk‑on in growth allocations.
400 episodes
Comments
0Be the first to comment
Sign up now and become a member of the Alpha Casts - AI Market Intelligence community!